SINGAPORE — Indian drugmaker Cadila Healthcare is about to start a phase three clinical trial for a potential coronavirus vaccine, its chairman told CNBC. “We’re now moving into phase three, which is going to start very, very soon,” Pankaj Patel told CNBC’s “Street Signs Asia” on Tuesday. He said the trial will involve about 30,000 volunteers and will take about three to three-and-a-half months to complete. The pharmaceutical company, which is also known as Zydus Cadila, said Sunday that it received approval from India’s drug regulator to begin the phase…

Read More